Pieris Pharmaceuticals, Inc. (PIRS)
| Market Cap | 156.72M |
| Revenue (ttm) | 44.72M |
| Net Income (ttm) | -26.43M |
| Shares Out | 54.34M |
| EPS (ttm) | -0.49 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | March 3 |
| Last Price | $2.68 |
| Previous Close | $2.72 |
| Change ($) | -0.04 |
| Change (%) | -1.47% |
| Day's Open | 2.72 |
| Day's Range | 2.61 - 2.80 |
| Day's Volume | 97,566 |
| 52-Week Range | 1.60 - 3.64 |
BOSTON, MA / ACCESSWIRE / January 19, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Antical...
Pieris Pharmaceuticals, Inc. (PIRS) CEO Steve Yoder on Q3 2020 Results - Earnings Call Transcript
Pieris Pharmaceuticals (PIRS) delivered earnings and revenue surprises of -62.50% and -67.29%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead ...
Shares of Pieris Pharmaceuticals (NASDAQ:PIRS) remained unaffected after the company reported Q3 results.
Pieris Pharmaceuticals, Inc. (PIRS) CEO Steve Yoder on Q2 2020 Results - Earnings Call Transcript
Shares of Pieris Pharmaceuticals (NASDAQ:PIRS) rose 8% in pre-market trading after the company reported Q2 results.
NEW YORK, July 21, 2020 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors Pieris Pharmaceuticals, Inc. ("Pieris" or the "Company") (NASDAQ: PIRS).
Pieris Pharmaceuticals' (PIRS) CEO Steve Yoder on Q1 2020 Results - Earnings Call Transcript
Pieris Pharmaceuticals (PIRS) delivered earnings and revenue surprises of 56.25% and 40.58%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for th...
Pieris Pharmaceuticals (PIRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Pieris Pharmaceuticals, Inc. (PIRS) CEO Stephen Yoder on Q4 2019 Results - Earnings Call Transcript
Pieris Pharmaceuticals (PIRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Recent activities like mergers and collaboration have boosted the gene therapy space this year, the broad and intriguing pipelines shows that the segment is poised to grow.
Recent activities like mergers and collaboration have boosted the gene therapy space this year, the broad and intriguing pipelines shows that the segment is poised to grow.
Pieris Pharmaceuticals, Inc. (PIRS) CEO Stephen Yoder on Q3 2019 Results - Earnings Call Transcript
Pieris Pharmaceuticals (PIRS) delivered earnings and revenue surprises of 78.26% and 141.15%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead f...
The stock of Pieris Pharmaceuticals has made a nice move so far in September.
Pieris Pharmaceuticals' (PIRS) CEO Steve Yoder on Q2 2019 Results - Earnings Call Transcript
Here are four stocks that appear to be at or near a breakout point: Enphase Energy, Inc.
Investors need to pay close attention to Pieris Pharmaceuticals (PIRS) stock based on the movements in the options market lately.
Shares have fallen by 30% since my initial and update articles.
Pieris Pharmaceuticals, Inc. (PIRS) CEO Stephen Yoder on Q1 2019 Results - Earnings Call Transcript
Pieris Pharmaceuticals (PIRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
About PIRS
Pieris Pharmaceuticals, a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs in the United States. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids. Its lead respiratory program includes PRS-060, a drug candidate, which is in Phase I clinical trial that binds to IL-4Ra for the treatment of asthma and other inflammatory diseases; and ... [Read more...]
| Industry Biotechnology | |
| CEO Stephen Yoder | Employees 114 |
| Stock Exchange NASDAQ | Ticker Symbol PIRS |
Financial Performance
In 2019, PIRS's revenue was $46.28 million, an increase of 59.03% compared to the previous year's $29.10 million. Losses were -$25.47 million, -4.80% less than in 2018.
Analyst Forecasts
According to 6 analysts, the average rating for PIRS stock is "Strong Buy." The 12-month stock price forecast is 9.00, which is an increase of 235.82% from the latest price.